MX2019003447A - Metodos para mejorar la terapia de bloqueo del punto de control inmune mediante la modulacion del microbioma. - Google Patents

Metodos para mejorar la terapia de bloqueo del punto de control inmune mediante la modulacion del microbioma.

Info

Publication number
MX2019003447A
MX2019003447A MX2019003447A MX2019003447A MX2019003447A MX 2019003447 A MX2019003447 A MX 2019003447A MX 2019003447 A MX2019003447 A MX 2019003447A MX 2019003447 A MX2019003447 A MX 2019003447A MX 2019003447 A MX2019003447 A MX 2019003447A
Authority
MX
Mexico
Prior art keywords
microbiome
methods
immune checkpoint
modulating
checkpoint blockade
Prior art date
Application number
MX2019003447A
Other languages
English (en)
Inventor
Wargo Jennifer
Gopalakrishnan Vancheswaran
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=61760978&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019003447(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Texas filed Critical Univ Texas
Publication of MX2019003447A publication Critical patent/MX2019003447A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A61K35/04—Tars; Bitumens; Mineral oils; Ammonium bituminosulfonate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11—Medicinal preparations comprising living procariotic cells
    • A61K2035/115—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

En la presente se proporcionan métodos y composiciones para el tratamiento del cáncer mediante la modulación del microbioma para mejorar la eficacia del bloqueo del punto de control inmune. El microbioma puede modularse mediante la administración de butirato y/o bacterias productoras de butirato. En la presente también se proporcionan métodos para determinar una respuesta a un inhibidor del punto de control inmune al identificar si un sujeto tiene un perfil microbiano favorable.
MX2019003447A 2016-09-27 2017-09-27 Metodos para mejorar la terapia de bloqueo del punto de control inmune mediante la modulacion del microbioma. MX2019003447A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662400372P 2016-09-27 2016-09-27
US201762508885P 2017-05-19 2017-05-19
US201762557566P 2017-09-12 2017-09-12
PCT/US2017/053717 WO2018064165A2 (en) 2016-09-27 2017-09-27 Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome

Publications (1)

Publication Number Publication Date
MX2019003447A true MX2019003447A (es) 2019-08-29

Family

ID=61760978

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2019003447A MX2019003447A (es) 2016-09-27 2017-09-27 Metodos para mejorar la terapia de bloqueo del punto de control inmune mediante la modulacion del microbioma.
MX2022003895A MX2022003895A (es) 2016-09-27 2019-03-26 Metodos para mejorar la terapia de bloqueo del punto de control inmune mediante la modulacion del microbioma.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022003895A MX2022003895A (es) 2016-09-27 2019-03-26 Metodos para mejorar la terapia de bloqueo del punto de control inmune mediante la modulacion del microbioma.

Country Status (10)

Country Link
US (3) US11395838B2 (es)
EP (1) EP3518946A4 (es)
JP (2) JP7542946B2 (es)
KR (1) KR102530297B1 (es)
CN (2) CN116196425A (es)
AU (1) AU2017335732A1 (es)
BR (1) BR112019006041A2 (es)
CA (1) CA3038076A1 (es)
MX (2) MX2019003447A (es)
WO (1) WO2018064165A2 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4005386A1 (en) 2015-05-06 2022-06-01 SNIPR Technologies Limited Altering microbial populations & modifying microbiota
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
US11395838B2 (en) 2016-09-27 2022-07-26 Board Of Regents, The University Of Texas System Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome
US11571446B2 (en) * 2016-11-18 2023-02-07 Sanford Bumham Prebys Medical Discovery Institute Gut microbiota and treatment of cancer
CN111295394B (zh) * 2017-08-11 2024-06-11 豪夫迈·罗氏有限公司 抗cd8抗体及其用途
BR112020017090A8 (pt) 2018-02-23 2022-07-05 Crestovo Holdings Llc Imunoterapias relacionadas com microbioma
WO2019178542A1 (en) * 2018-03-16 2019-09-19 Persephone Biome, Inc. Compositions for modulating gut microflora populations, enhancing drug potency and treating cancer, and methods for making and using same
EP3773685A1 (en) 2018-03-25 2021-02-17 SNIPR Biome ApS. Treating & preventing microbial infections
US10760075B2 (en) 2018-04-30 2020-09-01 Snipr Biome Aps Treating and preventing microbial infections
SG11202011031UA (en) * 2018-05-11 2020-12-30 4D Pharma Res Ltd Compositions comprising bacterial strains
WO2019240218A1 (ja) * 2018-06-14 2019-12-19 株式会社明治 免疫チェックポイント阻害療法を促進するための組成物
CN110638838B (zh) * 2018-06-26 2021-07-06 瑞微（深圳）生物科技有限公司 阿克曼粘细菌或普氏菌在制备用于增强抗肿瘤免疫功能的药物中的应用
WO2019009438A1 (ja) * 2018-09-21 2019-01-10 株式会社日本自然発酵 免疫チェックポイント抑制剤
JP7486479B2 (ja) * 2018-10-13 2024-05-17 メモリアル スローン ケタリング キャンサー センター Ｃａｒ ｔ細胞療法応答不良のリスクがある対象を識別および処置するための方法および組成物
US11851663B2 (en) 2018-10-14 2023-12-26 Snipr Biome Aps Single-vector type I vectors
WO2020079021A1 (en) * 2018-10-15 2020-04-23 Pharmabiome Ag Consortia of living bacteria useful for treatment of cancer related diseases, particularly graft versus host disease
AU2019384816A1 (en) * 2018-11-21 2021-06-24 Board Of Regents, The University Of Texas System Methods and compositions for treating cancer
WO2020118232A1 (en) * 2018-12-07 2020-06-11 President And Fellows Of Harvard College Identification of gut bacteria that promote an anti-tumor response to immunotherapy
US20220082554A1 (en) * 2019-01-04 2022-03-17 Kyoto University Prediction and/or Determination Marker for Effectiveness of Treatment with Drug Containing PD-1 Signal Inhibitor
GB201900754D0 (en) * 2019-01-18 2019-03-06 Mars Inc Monitoring tools and diagnostic methods
CN109680085B (zh) * 2019-01-22 2021-01-29 深圳未知君生物科技有限公司 基于肠道微生物信息预测治疗响应性的模型
US20220196667A1 (en) * 2019-04-01 2022-06-23 Board Of Regents, The University Of Texas System Tumor microbiome signature and therapeutic use of fecal microbiota transplantation on pancreatic cancer patients
CN109966320B (zh) * 2019-04-26 2022-08-05 青岛东海药业有限公司 凝结芽孢杆菌在制备诱导抗肿瘤免疫及免疫检查点抑制剂增敏制剂中的应用
KR20200134883A (ko) 2019-05-24 2020-12-02 주식회사 엘지화학 전고체전지용 음극의 제조방법
US20220370553A1 (en) * 2019-07-31 2022-11-24 Sanford Burnham Prebys Medical Discovery Institute Prebiotic-induced anti-tumor immunity
US20220339212A1 (en) 2019-08-28 2022-10-27 Xbiome Inc. Compositions comprising bacterial species and methods related thereto
CA3151747A1 (en) * 2019-09-23 2021-04-01 James J. MOON Compositions and methods for increasing the efficacy of immunotherapies and vaccines
KR102485269B1 (ko) * 2019-10-18 2023-01-06 주식회사 지놈앤컴퍼니 비피도박테리움 비피덤을 포함하는 면역력 증강 또는 개선용 조성물
MX2022005157A (es) * 2019-11-01 2022-08-31 Uti Lp Aprovechamiento de la energia de la microbiota y los metabolitos para el tratamiento del cancer.
WO2021127235A1 (en) * 2019-12-20 2021-06-24 Persephone Biosciences, Inc. Compositions for modulating gut microflora populations, enhancing drug potency and treating cancer, and methods for making and using same
IL271775A (en) * 2019-12-31 2021-06-30 Biomica Ltd A microbial consortium and its uses
KR102472648B1 (ko) * 2020-01-02 2022-12-01 인제대학교 산학협력단 염증성 장질환 환자의 미생물 군집 평가 방법
WO2021141828A1 (en) * 2020-01-10 2021-07-15 Assembly Biosciences, Inc. Compositions comprising bacterial species and methods related thereto
KR20210101620A (ko) * 2020-02-10 2021-08-19 주식회사 천랩 패칼리박테리움 속 균주를 이용한 항암 치료
AU2021220620A1 (en) * 2020-02-12 2022-08-18 Universität Zürich A bacterial composition for the treatment of cancer
CA3177351A1 (en) * 2020-02-18 2021-08-26 Memorial Sloan-Kettering Cancer Center Methods and compositions for identifying and treating subjects at risk of poor cancer survival
CN111110852A (zh) * 2020-02-27 2020-05-08 上海上药信谊药厂有限公司 抗肿瘤组合物
WO2021176036A1 (en) * 2020-03-06 2021-09-10 Leibniz-Institut Für Naturstoff-Forschung Und Infektionsbiologie E. V. Hans-Knöll-Institut (Hki) Method for the modulation of cancer treatment based on analyzing the gut microbiome
US20220290226A1 (en) * 2020-03-20 2022-09-15 Zoe Global Limited Microbiome fingerprints, dietary fingerprints, and microbiome ancestry, and methods of their use
WO2021216618A1 (en) * 2020-04-21 2021-10-28 City Of Hope Compositions and methods comprising clostridium butyricum for the treatment of cancer
CN111494637A (zh) * 2020-04-28 2020-08-07 东华大学 一种抗肿瘤联合制剂及其应用
GB202007452D0 (en) * 2020-05-19 2020-07-01 Microbiotica Ltd Threrapeutic bacterial composition
CN113106163B (zh) * 2020-05-27 2024-06-04 微度(苏州)生物科技有限公司 一种用于结直肠癌早期诊断的生物标志物组合物及应用
AU2021355240A1 (en) * 2020-09-30 2023-05-25 National Cancer Center Enhancement of antitumor effect of immune checkpoint inhibitor through administration of intestinal ruminococcaceae bacterium
CA3198416A1 (en) * 2020-10-21 2022-04-28 Gusto Global, Llc Microbial-based compositions for systemic inflammation control
CN112458031B (zh) * 2020-12-23 2022-04-29 江南大学 一株源自白酒酿造窖泥的产乳酸型己酸菌及其应用
WO2022159569A1 (en) * 2021-01-20 2022-07-28 Memorial Sloan Kettering Cancer Center Peripheral blood phenotype linked to outcomes after immunotherapy treatment
CN112877268A (zh) * 2021-04-22 2021-06-01 上海耀旦生物科技有限公司 一种增强免疫检查点抑制剂治疗效应的干酪乳杆菌株及其应用
CN115998771A (zh) * 2021-07-16 2023-04-25 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一种细菌在制备免疫检查点抑制剂的增效剂中的应用
CN114306616B (zh) * 2022-01-12 2023-04-28 广州知易生物科技有限公司 脆弱拟杆菌和免疫检查点抑制剂的新应用
CN114425080B (zh) * 2022-01-12 2023-08-29 广州知易生物科技有限公司 脆弱拟杆菌与pd-1或pd-l1抗体联合用药治疗生殖泌尿系统癌症的应用
CN114344340B (zh) * 2022-01-12 2023-07-25 广州知易生物科技有限公司 脆弱拟杆菌与pd-1及pd-l1抗体联合用药治疗呼吸系统肿瘤中的应用
CN114344338B (zh) * 2022-01-12 2023-08-04 广州知易生物科技有限公司 脆弱拟杆菌和/或其两性离子荚膜多糖的新应用
WO2023140721A1 (ko) * 2022-01-21 2023-07-27 가톨릭대학교 산학협력단 위암 환자 장내균총 분석을 통한 면역 저하 진단과 장내균총을 이용한 테라그노시스 조성물
KR102627070B1 (ko) * 2022-06-27 2024-01-23 한국과학기술원 미생물, 및 면역관문 억제제를 유효성분으로 포함하는,고 당분 환경에서의 뇌종양 예방 또는 치료용 조성물
GB202209518D0 (en) 2022-06-29 2022-08-10 Snipr Biome Aps Treating & preventing E coli infections
NL2032642B1 (en) * 2022-07-29 2024-02-06 Academisch Ziekenhuis Leiden Improvement of muscle mass and strength
WO2024102452A1 (en) * 2022-11-10 2024-05-16 Board Of Regents, The University Of Texas System Hepatoprotective probiotic compositions
CN116042827B (zh) * 2022-12-07 2023-12-22 臻傲生物科技检测(深圳)有限公司 预测结直肠癌风险的新型微生物标志物
CN116087499B (zh) * 2023-02-20 2023-10-31 深圳裕康医学检验实验室 一种癌样本的染色方法及试剂盒
CN117363511B (zh) * 2023-08-18 2024-09-03 四川大学 一种可改善阴道炎疾病的融合魏斯氏菌及其应用
CN116785277B (zh) * 2023-08-23 2023-11-07 中国农业大学 染料木黄酮在制备调控肠道菌丰度的制剂中的应用
CN117344018B (zh) * 2023-09-28 2024-04-30 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） 一组用于预测鼻咽癌复发转移风险的瘤内菌标志物及其应用
CN117625500B (zh) * 2024-01-24 2024-04-02 中山大学 一种胃梭菌及其应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4870287A (en) 1988-03-03 1989-09-26 Loma Linda University Medical Center Multi-station proton beam therapy system
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
JPH08506247A (ja) 1993-07-09 1996-07-09 アムジェン ボールダー インコーポレイテッド 組換えｃｔｌａ４ポリペプチドおよびその製造方法
DE4440528C2 (de) 1994-11-12 2001-02-01 Lohmann Therapie Syst Lts Implantierbare Vorrichtung zur Verabreichung von Wirkstoffen an Pflanzen
US5763488A (en) 1995-10-30 1998-06-09 Vertex Pharmaceuticals Incorporated Methods and compositions using butyrate esters of threitol
US5760395A (en) 1996-04-18 1998-06-02 Universities Research Assoc., Inc. Method and apparatus for laser-controlled proton beam radiology
US5844905A (en) 1996-07-09 1998-12-01 International Business Machines Corporation Extensions to distributed MAC protocols with collision avoidance using RTS/CTS exchange
AU6703198A (en) 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
PT2112166T (pt) 1998-12-23 2019-01-30 Pfizer Anticorpos monoclonais humanos contra ctla-4
KR100942863B1 (ko) 1999-08-24 2010-02-17 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
PT1639013E (pt) 2003-07-02 2012-12-03 Innate Pharma Anticorpos contra receptor nk pan-kir2dl e a sua utilização em diagnóstico e terapêutica
PT1648507T (pt) 2003-07-24 2017-03-20 Innate Pharma Sa Métodos e composições para aumentar a eficácia de anticorpos terapêuticos utilizando compostos potenciadores de células nk
DE102004031929A1 (de) 2004-06-23 2006-01-12 Felsomat Gmbh & Co Kg Modulare Automationszelle
AU2005259221B2 (en) 2004-07-01 2011-02-10 Innate Pharma Antibodies binding to receptors KIR2DL1, -2, 3 but not KIR2DS4 and their therapeutic use
ATE531733T1 (de) 2005-01-06 2011-11-15 Novo Nordisk As Kir-bindende wirkstoffe und verfahren zu ihrer verwendung
WO2006072625A2 (en) 2005-01-06 2006-07-13 Novo Nordisk A/S Anti-kir combination treatments and methods
NZ563193A (en) 2005-05-09 2010-05-28 Ono Pharmaceutical Co Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
CA2623109C (en) 2005-10-14 2019-02-19 Innate Pharma Nk cell-depleting antibodies for treating immunoproliferative disorders
WO2008084106A1 (en) 2007-01-11 2008-07-17 Novo Nordisk A/S Anti-kir antibodies, formulations, and uses thereof
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
ES2437327T3 (es) 2007-06-18 2014-01-10 Merck Sharp & Dohme B.V. Anticuerpos para el receptor PD-1 humano de muerte programada
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
JP2011512332A (ja) 2008-02-11 2011-04-21 キュアー テック リミテッド 腫瘍治療のためのモノクローナル抗体
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
US8119129B2 (en) 2008-08-01 2012-02-21 Bristol-Myers Squibb Company Combination of anti-CTLA4 antibody with dasatinib for the treatment of proliferative diseases
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
US20110159023A1 (en) 2008-08-25 2011-06-30 Solomon Langermann Pd-1 antagonists and methods for treating infectious disease
WO2010065939A1 (en) 2008-12-05 2010-06-10 Indiana University Research & Technology Corporation Combination therapy to enhace nk cell mediated cytotoxicty
KR101767168B1 (ko) 2009-06-29 2017-08-10 일리노이즈 툴 워크스 인코포레이티드 2상 스프링
WO2011014438A1 (en) 2009-07-31 2011-02-03 N.V. Organon Fully human antibodies to btla
EP2473523A2 (en) 2009-08-31 2012-07-11 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
JP2013512251A (ja) 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Ｐｄ−ｌ１／ｐｄ−ｌ２の同時阻害
US9629881B2 (en) 2010-02-01 2017-04-25 Rebiotix, Inc. Bacteriotherapy for clostridium difficile colitis
EP2536745B1 (en) 2010-02-19 2016-05-11 Xencor, Inc. Novel ctla4-ig immunoadhesins
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
AR083957A1 (es) 2010-11-22 2013-04-10 Innate Pharma Sa Tratamiento para modular las celulas nk y metodos para tratar malignidad hematologica
EA036545B1 (ru) 2011-05-25 2020-11-20 Иннейт Фарма, С.А. Анти-kir антитела для лечения воспалительных заболеваний
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
AU2012296613B2 (en) 2011-08-15 2016-05-12 Amplimmune, Inc. Anti-B7-H4 antibodies and their uses
WO2013067492A1 (en) 2011-11-03 2013-05-10 The Trustees Of The University Of Pennsylvania Isolated b7-h4 specific compositions and methods of use thereof
US10238694B2 (en) 2011-12-01 2019-03-26 The University Of Tokyo Human-derived bacteria that induce proliferation or accumulation of regulatory T cells
JP2014022858A (ja) 2012-07-17 2014-02-03 Murata Mfg Co Ltd 電力増幅器
US10098020B2 (en) 2012-08-03 2018-10-09 Intel Corporation Techniques for sending or receiving channel state information reports associated with a coordinated multi-point scheme
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
WO2015016718A1 (en) 2013-08-02 2015-02-05 Bionovion Holding B.V. Combining cd27 agonists and immune checkpoint inhibition for immune stimulation
BR112016005408B1 (pt) 2013-09-13 2023-03-21 Beigene Switzerland Gmbh Anticorpos anti-pd1, f(ab) ou f(ab)2 e uso referido anticorpo para tratamento de cancer ou infecção viral
WO2015066625A1 (en) 2013-11-01 2015-05-07 Washington University Methods to establish and restore normal gut microbiota function of subject in need thereof
EP2876167A1 (en) 2013-11-21 2015-05-27 Institut Gustave Roussy Microbiota composition, as a marker of responsiveness to chemotherapy, and use of microbial modulators (pre-,pro- or synbiotics) for improving the efficacy of a cancer treatment
WO2015095241A2 (en) * 2013-12-16 2015-06-25 Seres Health, Inc. Bacterial compositions and methods of use thereof for treatment of immune system disorders
MX2016012891A (es) * 2014-03-31 2017-10-12 Univ Johns Hopkins Uso de bacterias, productos bacterianos, y otras entidades inmunorreguladoras en combinacion con anticuerpos anti antigeno 4 de linfocitos t citotoxicos (ctla-4) y/o anti proteina 1 de muerte celular programada (pd-1) para tratar neoplasias de tumor solido.
JP6617935B2 (ja) 2014-04-10 2019-12-11 国立研究開発法人理化学研究所 Ｔｈ１７細胞の誘導のための組成物及び方法
WO2016063263A2 (en) 2014-10-23 2016-04-28 Institut Gustave Roussy Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker
WO2016196605A1 (en) 2015-06-01 2016-12-08 The University Of Chicago Treatment of cancer by manipulation of commensal microflora
CN105296590B (zh) 2015-09-30 2019-04-19 上海锐翌生物科技有限公司 大肠癌标志物及其应用
WO2017172894A2 (en) * 2016-03-30 2017-10-05 The Trustees Of Columbia University In The City Of New York Methods of preventing, treating and detecting colorectal cancer using butyrate producing bacteria
GB201609811D0 (en) 2016-06-05 2016-07-20 Snipr Technologies Ltd Methods, cells, systems, arrays, RNA and kits
US11395838B2 (en) 2016-09-27 2022-07-26 Board Of Regents, The University Of Texas System Methods for enhancing immune checkpoint blockade therapy by modulating the microbiome
KR102644935B1 (ko) 2016-12-22 2024-03-07 인스티튜트 구스타브 루시 항-PD1/PD-L1/PD-L2 항체에 대한 반응성의 마커로서의 미생물총 조성물, 및 항-PD1/PD-L1/PD-L2 Ab-기반 치료의 효능을 개선하기 위한 미생물 조정제의 용도
RU2020134741A (ru) 2018-03-28 2022-04-28 Серес Терапеутикс, Инк. Микробиомные композиции для лечения рака

Also Published As

Publication number Publication date
AU2017335732A1 (en) 2019-04-04
JP2020500151A (ja) 2020-01-09
US20240173361A1 (en) 2024-05-30
BR112019006041A2 (pt) 2019-09-03
US11395838B2 (en) 2022-07-26
MX2022003895A (es) 2022-04-19
JP7542946B2 (ja) 2024-09-02
RU2019108925A (ru) 2020-10-29
US20230109343A1 (en) 2023-04-06
CN110267651B (zh) 2023-09-01
KR102530297B1 (ko) 2023-05-10
CN116196425A (zh) 2023-06-02
WO2018064165A2 (en) 2018-04-05
US20200129569A1 (en) 2020-04-30
JP2023029829A (ja) 2023-03-07
KR20230066654A (ko) 2023-05-16
RU2019108925A3 (es) 2021-12-20
CA3038076A1 (en) 2018-04-05
EP3518946A4 (en) 2020-09-09
CN110267651A (zh) 2019-09-20
WO2018064165A3 (en) 2019-06-06
KR20190061042A (ko) 2019-06-04
EP3518946A2 (en) 2019-08-07

Similar Documents

Publication Publication Date Title
MX2022003895A (es) Metodos para mejorar la terapia de bloqueo del punto de control inmune mediante la modulacion del microbioma.
CY1120373T1 (el) Συνθεσεις που περιλαμβανουν βακτηριακα στελεχη
WO2016070051A3 (en) Combination therapy for treatment of disease
CL2017001464A1 (es) Modulación inmunológica
WO2018112365A3 (en) Methods of treating colorectal cancer and melanoma using parabacteroides goldsteinii
EA201790180A1 (ru) Способы и терапевтические комбинации для лечения опухолей
MD3209381T2 (ro) Compoziții care conțin tulpini bacteriene
WO2017134302A3 (en) Targeted therapeutic agents and uses thereof
MX2021013837A (es) Enfoque de inmunoterapias de combinacion para el tratamiento del cancer.
CY1119419T1 (el) C1-inh συνθεσεις για χρηση στην προληψη και αγωγη κληρονομικου αγγειοοιδηματος (ηαε)
GB2541571A (en) Pharmaceutical compositions
PH12015502161A1 (en) Therapeutic compounds and compositions
MX2022008868A (es) Tratamiento del cancer con tg02.
WO2017007941A3 (en) Compositions and methods for identification, assessment prevention, and treatment of cancer using slncr isoforms
MX2019007243A (es) Inhibidores de ectonucleotidasa y metodos de uso de los mismos.
MX364691B (es) Preparacion de enjuague bucal mejorada.
EA201591925A1 (ru) Терапевтические композиции и их применение
WO2017040666A3 (en) Combination therapy for treatment of disease
WO2019099578A8 (en) Use of imidazopyrimidine for modulating human immune response
EP3702470A3 (en) Reduction of er-mam-localized app-c99 and methods of treating alzheimer's disease
PH12016501838A1 (en) Compounds and their methods of use
EP4324477A3 (en) Oxabicycloheptanes for modulation of immune response
MX2022003739A (es) Inhibidores de pla2 secretados para usarse en el tratamiento inmediato de envenenamiento por himenopteros.
BR112017005993A2 (pt) derivados de peptídeo inovadores e usos dos mesmos
EA201592012A1 (ru) Применение флагеллина для улучшенной химиотерапии